
Disclosure Policy

Orthocell Limited (ABN 57 118 897 135) Adopted by the Board on 14 August 2024

1 Introduction

- (a) Under continuous disclosure laws, Orthocell Limited (**Orthocell** or **Company**) must immediately notify the Australian Securities Exchange (**ASX**) of materially price sensitive information (unless an exception applies). ASX requires that the share market is kept continuously informed of such information.
- (b) Failure to notify ASX can be a serious criminal offence, exposing Orthocell, its managers and directors to imprisonment, fines and damages.
- (c) For the purposes of this policy, “**Orthocell Person**” means the following:
 - (i) all Directors and Senior Management and any other person designated an Orthocell Person by the Board in writing; and
 - (ii) also includes:
 - (A) a company or trust controlled by any of the persons referred to in sub-paragraph (i) above; and
 - (B) for the purposes of any applicable Blackout Periods, a spouse (including a de facto spouse), child (including a step-child or adopted child), a close relative, a person financially dependent on or acting in concert with any of the persons referred to in sub-paragraph (i) above.

Blackout Periods are times when Orthocell Persons must not deal in the Company’s securities.

Directors and Senior Management means each director of Orthocell, Chief Executive Officer and Managing Director, the Chief Operating Officer, Chief Financial Officer and Company Secretary of Orthocell, Key Management Personnel and persons as the Board decides from time to time.

Key Management Personnel has the meaning given in the *Corporations Act 2001* (Cth).

- (d) This policy is available in the Invest section of Orthocell’s website.

2 Continuous disclosure principle

- (a) ASX listing rule (**LR**) 3.1 requires Orthocell to immediately notify the ASX if it has, or becomes aware of, any information concerning Orthocell that a reasonable person would expect to have a material effect on the price or value of Orthocell’s securities were that information to be generally available. This is known as the

continuous disclosure obligation. Orthocell is also required by section 674 and 674A of the Corporations Act to comply with this obligation. In this context, ASX has confirmed in Guidance Note 8 that “immediately” means “promptly and without delay”.

- (b) LR 15.7 requires that Orthocell must not release information that is for release to the market to any person until it has given the information to the ASX and has received acknowledgment that the ASX has released the information to the market.
- (c) The continuous disclosure obligation does not apply if the exception to the obligation outlined in section 3 of this policy applies.
- (d) Any material price sensitive information must be disclosed to the ASX in accordance with this policy.

3 Exception to the continuous disclosure principle

3.1 Availability of the exception

- (a) Disclosure under LR 3.1 is not required if each of the following is satisfied in relation to the information:
 - (i) the information is confidential and the ASX has not formed the view that the information has ceased to be confidential; and
 - (ii) one or more of the following applies:
 - (A) it would be a breach of a law to disclose the information;
 - (B) the information concerns an incomplete proposal or negotiation;
 - (C) the information comprises matters of supposition or is insufficiently definite to warrant disclosure;
 - (D) the information is generated for the internal management purposes of Orthocell; or
 - (E) the information is a trade secret; and
 - (iii) a reasonable person would not expect the information to be disclosed.
- (b) All three elements set out above must be satisfied before the exception to the continuous disclosure obligation applies. Should any of these elements no longer be satisfied, Orthocell must immediately disclose the information to the ASX in accordance with this policy.

3.2 A false market may cause the exception to be lost

LR 3.1B provides that if the ASX considers that there is, or is likely to be, a false market in Orthocell's securities, and requests information from Orthocell to correct or prevent the false market, Orthocell must give the ASX the information needed to correct or prevent the false market.

4 Disclosure Committee

- (a) Orthocell's board of directors (**Board**) has established a disclosure committee (**Committee**) comprising of:
 - (i) the Chair of the Board;
 - (ii) Orthocell's Chief Executive Officer and Managing Director (**CEO**);
 - (iii) Orthocell's Chief Operating Officer;
 - (iv) one Australian based independent Non-Executive Director; and
 - (v) Orthocell's Company Secretary (who, for administrative convenience only, is primarily responsible for overseeing and coordinating all communication with the ASX, investors, analysts, brokers, the media and the public) (**Disclosure Officer**).
- (b) The Committee's responsibilities include:
 - (i) determining what information will be disclosed by Orthocell to the ASX;
 - (ii) implementing procedures to ensure that, if required:
 - (A) disclosures to the ASX can be made immediately; and
 - (B) trading halt requests can be lodged with the ASX immediately;
 - (iii) preparing (or overseeing the preparation of) external announcements (other than categories of routine announcements that the Committee determines may be prepared and released without its prior review, if any);
 - (iv) reviewing and approving proposed external announcements for release to ASX, or, if (d) applies, referring to the Board for approval; and
 - (v) providing the Board with copies of all material market announcements promptly after they have been made.
- (c) The Committee must consult with the Board, CEO, senior management and external advisers as it considers necessary, including where there is doubt as to whether certain information should be disclosed.

- (d) If the CEO or the Committee considers that an announcement is of such a nature that it ought to be reviewed and approved by the Board or the Board has directed that the nature of such an announcement requires Board approval, then the Company Secretary must:
 - (i) take all steps necessary to circulate a draft of the announcement as soon as practicable to the Board for it to consider and approve the announcement; and
 - (ii) take such other steps as the Committee determines are necessary to comply with Orthocell's continuous disclosure obligations, including, if necessary, liaising with ASX to request a trading halt or suspension from trading until the Board is able to meet.
- (e) A quorum of the Committee is two members. If a quorum cannot be formed from the Committee members listed in paragraph 4(a), the following will be added as members of the Committee (in the order specified), until a quorum can be formed:
 - (i) the Chair of the Audit and Risk Management Committee (if one has been appointed by the Board);
 - (ii) the Chair of the Remuneration and Nomination Committee; and
 - (iii) any other director of the Company.

5 Reporting obligations

- (a) Where a continuous disclosure obligation arises, disclosure should not be delayed to accommodate the availability of members of the Committee or, if applicable, the Board. If either the Committee (or, in the case of announcements to be approved by the Board, the Board) is unavailable to make a disclosure decision, the Disclosure Officer must take such other steps as he or she determines is necessary to comply with Orthocell's continuous disclosure obligations, including, if necessary, liaising with ASX to request a trading halt or suspension from trading until the Committee or the Board is able to meet.
- (b) The Disclosure Officer is responsible for ensuring that all Committee or Board decisions that must be disclosed to the ASX are dealt with by an appropriate company announcement and that any routine announcement is also accurate, balanced and expressed in a clear and objective manner.
- (c) All Orthocell Persons (which for the purposes of clause 5 includes all officers, employees and all people who work at Orthocell, including contractors and consultants) are required to immediately advise a member of the Committee of any information that they believe may be price sensitive or any issues which could develop into price sensitive information. If an Orthocell Person has doubt as to

whether information concerning Orthocell is price sensitive, the Orthocell Person must report that information to their manager, who must then report that information to a member of the Committee. The Orthocell Person must not disclose that information to anyone outside Orthocell before the ASX is notified.

- (d) If any Orthocell Person becomes aware that:
 - (i) there may have been inadvertent disclosure of material price sensitive information (which has not yet been disclosed to the ASX) during any communication with external parties; or
 - (ii) confidential Orthocell information may have been leaked (whatever its source),

he or she should immediately notify their manager, who must immediately then notify a member of the Committee. The Committee will determine the appropriate next steps.

6 Disclosure

- (a) If the Committee or Board (as applicable) approves the disclosure of information, the Disclosure Officer must immediately lodge that information with the ASX in the manner prescribed by the ASX Listing Rules.
- (b) Orthocell must not release information that is for release to the market to any person until it has given the information to the ASX and has received acknowledgment that the ASX has released the information to the market.
- (c) This policy and all information disclosed to the ASX in compliance with this policy will be promptly posted on Orthocell's corporate website following receipt of such an acknowledgement from the ASX and verification by the Disclosure Officer.

7 Trading halts

- (a) In exceptional circumstances, it may be necessary for Orthocell to request a trading halt to maintain fair, orderly and informed trading in Orthocell's shares and to manage disclosure issues (for example, if confidential price sensitive information is prematurely or inadvertently disclosed and an immediate release cannot be made).
- (b) Subject to the Board's direction, the Committee is responsible for all decisions in relation to trading halts. Unless otherwise provided in section 5 above, only the Disclosure Officer is authorised to request a trading halt and only in accordance with a decision by the Disclosure Committee or Board (as applicable).

8 False markets

- (a) In the event that the Board or any member of the Committee is aware that Orthocell is relying on an exception to its continuous disclosure obligations, they must notify each other member of the Committee and the Committee may request the Disclosure Officer (or such other person as the Committee thinks fit) to monitor:
 - (i) the market price of Orthocell's shares;
 - (ii) major national and local newspapers;
 - (iii) if Orthocell (or any advisers of Orthocell working on the particular transaction) has access to them, major news wire services such as Reuters and Bloomberg;
 - (iv) any investor blogs, chat-sites or other social media that Orthocell is aware of that regularly post comments about Orthocell; and
 - (v) enquiries from analysts or journalists,

for signs that the information to be covered in a potential announcement may have leaked and, if it detects any such signs, to initiate discussions with ASX as soon as practicable.

- (b) Orthocell's general policy is to respond to market rumours or speculation by stating that "Orthocell does not respond to market rumours or speculation". However, if Orthocell receives a request from the ASX for information to correct or prevent a false market, the Disclosure Officer must (in consultation with the Committee and external advisers, if necessary) immediately provide that information to the ASX.

9 Briefing investors, analysts and the media

- (a) Orthocell Persons must ensure that they do not communicate material that a reasonable person would expect would have a material effect on the entity's securities to an external party except where that information has previously been released publicly through the ASX.
- (b) Ahead of any new and substantive investor or analyst presentation, a copy of the presentation materials must be released to ASX (even if the information in the presentation would not otherwise require market disclosure).
- (c) If any Orthocell Person participating in a briefing considers that a matter has been raised that might constitute a previously undisclosed material price or value sensitive matter, they must immediately refer the matter to a member of the Committee.

- (d) The only Orthocell Persons authorised to speak on behalf of Orthocell to investors, potential investors, analysts or the media are:
 - (i) the Chair of the Board;
 - (ii) the CEO;
 - (iii) the Chief Operating Officer; or
 - (iv) such other Orthocell Persons approved by the Chair of the Board.
- (e) Authorised spokespersons should clarify information that Orthocell has released publicly through the ASX but must not comment on material price or value sensitive issues that have not been disclosed to the market generally.
- (f) If a question is asked in a briefing which can only be answered by disclosing material price sensitive information which has not been publicly released, the relevant Orthocell Person must decline to answer the question or take the question on notice.
- (g) During the time:
 - (i) between the end of Orthocell's financial reporting periods (30 June and 31 December) and the announcement to the ASX of the financial results for those periods; and
 - (ii) between the end of the quarterly financial reporting periods (31 March and 30 September) and the announcement to the ASX of the financial results for those periods (while the Company is required to lodge an Appendix 4C),

(often termed blackout periods), further restrictions are imposed to help ensure that Orthocell does not inadvertently disclose price sensitive information. Generally, Orthocell may respond to requests for background information but will not hold meetings or briefings with individual or institutional investors, analysts or media representatives in relation to financial information, unless the CEO decides that it is appropriate for the Company to do so and the meeting or briefing will be the subject of a specific announcement to the market through the ASX. Only the CEO, or Chief Operating Officer, may respond to questions from the financial community during blackout periods.
- (h) All briefing and presentation materials which contain previously undisclosed information will be disclosed to the market through the ASX and placed on Orthocell's corporate website.

10 Earnings expectations and forecasts

- (a) Comments on expected earnings are confined to Orthocell's annual, half year financial reports, quarterly financial reports and the annual general meeting of

Orthocell (which would be communicated to the ASX at the time of meeting) and forecasts in a bidder's statement or prospectus. Any material change in a disclosed earnings expectation must be immediately announced to the ASX before being communicated to anyone outside Orthocell.

- (b) The Chief Operating Officer is responsible for monitoring analyst reports and consensus broker forecasts for Orthocell to determine whether to raise with the Committee and the Board whether an announcement to the ASX may be necessary to correct factual inaccuracies or historical matters. If the Chief Operating Officer becomes aware of any such inaccuracies or a material divergence between an analyst's or consensus forecast and Orthocell's own forecasts or earnings expectations, he or she shall liaise with the Committee so that the necessity for an announcement to the ASX and/or trading halt can be considered.
- (c) Any correction of factual inaccuracies by Orthocell does not imply an endorsement of the content of the report or forecast.

11 Breach of policy

Orthocell regards its continuous disclosure obligations as very important. Breach of this policy may lead to disciplinary action being taken against the employee, including dismissal in serious cases.

12 Reviews and changes to this policy

- (a) The Committee will review this policy annually or as often as it considers necessary to check it is operating effectively and consider whether changes are required.
- (b) The Board may change this policy (including the responsibilities of the Committee) from time to time by resolution.